Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Abstract Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a benefit to using ICIs in the neoadjuvant therapy of...

Full description

Bibliographic Details
Main Authors: Arafat Tfayli, Majd Al Assaad, Ghina Fakhri, Reem Akel, Hanine Atwi, Hady Ghanem, Fadi El Karak, Fadi Farhat, Kamal Al Rabi, Pierre Sfeir, Pierre Youssef, Ziad Mansour, Hazem Assi, Mohamad Haidar, Alain Abi Ghanem, Ibrahim Khalifeh, Fouad Boulos, Ramy Mahfouz, Bassem Youssef, Youssef Zeidan, Rachelle Bejjany, Fadlo Khuri
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Cancer Medicine
Subjects:
immune checkpoint inhibitors
neoadjuvant therapy
nonsmall cell lung cancer
oncogenic drivers
Online Access:https://doi.org/10.1002/cam4.3456

Internet

https://doi.org/10.1002/cam4.3456

Similar Items